| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Scoping commencing |
| Process | STA Standard |
| ID number | 3770 |
Provisional Schedule
| Committee meeting: 1 | 06 August 2024 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
| External Assessment Group | Newcastle NIHR TAR Team, Newcastle University |
Stakeholders
| Companies sponsors | Blueprint Medicines (Avapritinib) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | The UK Mastocytosis support group |
| Professional groups | Association of Cancer Physicians |
| British Society for Allergy and Clinical Immunology | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | Amarox – not participating |
| Aspire Pharma – not participating | |
| Atnahs Pharma UK – not participating | |
| Aurobindo Pharma - Milpharm – not participating | |
| Cipla EU – not participating | |
| Dr. Reddy's Laboratories – not participating | |
| Esteve Pharmaceuticals – not participating | |
| Lipomed – not participating | |
| Novartis Pharmaceuticals (imatinib, midostaurin) | |
| Rivopharm UK – not participating | |
| Roche – not participating | |
| Rosemont Pharmaceuticals – not participating | |
| Sandoz – not participating | |
| Zentiva – not participating | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 April 2024 | The first committee meeting discussion has now been scheduled for 6 August 2024. |
| 03 April 2024 | The company, Blueprint Medicines, has provided their evidence submission which is being reviewed by the External Academic Group, Centre for Reviews and Dissemination and Centre for Health Economics – York. To ensure that the committee gets the best evidence package possible, this will no longer be discussed at the committee meeting on 2 July 2024. The second committee meeting discussion will be rearranged, and we will update all stakeholders with the new date in due course. |
| 20 November 2023 | Invitation to participate |
| 18 July 2023 - 15 August 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3770 |
| 18 July 2023 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual